Jounce Therapeutics, Inc.
JNCEDelisted May 4, 2023- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001640455
Jounce Therapeutics, Inc. was delisted on May 4, 2023; its insiders filed their last Form 4 on May 5, 2023; 84 institutions reported holding it in 13F filings for Q1 2023, worth $64.1M in total; no superinvestor held it.
13F holders, Q2 2021
Institutional positions in Jounce Therapeutics, Inc. as of Jun 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 130
- +6 vs. Q1 2021
- Shares held
- 36.0M
- −820.6K (−2.2%) vs. Q1 2021
- Total value
- $244.8M
- −$133.5M (−35.3%) vs. Q1 2021
- New holders
- 20
- 65 more added
- Sold out
- 14
- 24 more reduced
Compare with Q1 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting JNCE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 1 | $917.8K |
| Q1 2023 | 84 | $64.1M |
| Q4 2022 | 85 | $39.8M |
| Q3 2022 | 102 | $99.5M |
| Q2 2022 | 102 | $129.3M |
| Q1 2022 | 113 | $287.1M |
| Q4 2021 | 124 | $342.9M |
| Q3 2021 | 115 | $270.6M |
| Q2 2021 | 130 | $244.8M |
| Q1 2021 | 124 | $378.3M |
Institutions, Q2 2021
Shares, value and share of portfolio for each institution holding Jounce Therapeutics, Inc.; share changes are against Q1 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Charles Schwab Investment Management Inc | 258,092 | $1.76M | 0.00% | +58,069+29.0% | Added |
| HealthCor Management, L.P. | 268,295 | $1.82M | 0.07% | +65,710+32.4% | Added |
| Omega Fund Management, LLC | 275,513 | $1.87M | 0.21% | 00.0% | Unchanged |
| Two Sigma Investments, LP | 297,629 | $2.02M | 0.01% | +202,780+213.8% | Added |
| JPMorgan Chase & Co | 330,303 | $2.25M | 0.00% | +165,028+99.9% | Added |
| Candriam Luxembourg S.C.A. | 337,398 | $2.29M | 0.02% | +337,393+6,747,860.0% | Added |
| Granahan Investment Management Inc | 357,817 | $2.43M | 0.05% | +18,848+5.6% | Added |
| Congress Asset Management Co | 358,399 | $2.44M | 0.02% | +255,629+248.7% | Added |
| Tekla Capital Management LLC | 382,237 | $2.60M | 0.08% | 00.0% | Unchanged |
| Northern Trust Corp | 427,885 | $2.91M | 0.00% | +175,285+69.4% | Added |
| State Street Corp | 438,765 | $2.98M | 0.00% | +132,486+43.3% | Added |
| Millennium Management LLC | 458,316 | $3.12M | 0.00% | +280,088+157.2% | Added |
| Victory Capital Management Inc | 485,173 | $3.30M | 0.00% | −1,856,832−79.3% | Reduced |
| Geode Capital Management, LLC | 529,515 | $3.60M | 0.00% | +186,990+54.6% | Added |
| Credit Suisse AG | 550,562 | $3.74M | 0.00% | +45,979+9.1% | Added |
| Sofinnova Investments, Inc. | 624,756 | $4.25M | 0.26% | +112,934+22.1% | Added |
| Erste Asset Management GmbH | 659,587 | $4.47M | 0.09% | +25,000+3.9% | Added |
| Assenagon Asset Management S.A. | 682,870 | $4.64M | 0.02% | +682,870 | New |
| Acadian Asset Management LLC | 703,919 | $4.79M | 0.02% | +218,774+45.1% | Added |
| FMR LLC | 790,934 | $5.38M | 0.00% | +49,900+6.7% | Added |
| Dimensional Fund Advisors LP | 1,227,280 | $8.35M | 0.00% | +166,849+15.7% | Added |
| Vanguard Group Inc | 1,406,825 | $9.57M | 0.00% | +46,060+3.4% | Added |
| Citadel Advisors LLC | 1,960,601 | $13.3M | 0.01% | +540.0% | Added |
| OrbiMed Advisors LLC | 2,147,400 | $14.6M | 0.15% | +323,800+17.8% | Added |
| Adage Capital Partners GP, L.L.C. | 2,428,023 | $16.5M | 0.03% | 00.0% | Unchanged |
| BlackRock Inc. | 2,457,099 | $16.7M | 0.00% | +617,800+33.6% | Added |
| TRV GP III, LLC | 3,048,780 | $20.7M | 3.62% | 00.0% | Unchanged |
| PFM Health Sciences, LP | 3,262,833 | $22.2M | 0.71% | 00.0% | Unchanged |
| TRV GP II, LLC | 4,447,829 | $30.2M | 89.29% | −2,052,520−31.6% | Reduced |
| Colony Group LLC | 10,000 | – | – | 00.0% | Unchanged |
| Caas Capital Management LP | 0 | $0 | 0.00% | −1,052,437−100.0% | Sold out |
| Avoro Capital Advisors LLC | 0 | $0 | 0.00% | −555,000−100.0% | Sold out |
| Asymmetry Capital Management, L.P. | 0 | $0 | 0.00% | −520,858−100.0% | Sold out |
| Maven Securities LTD | 0 | $0 | 0.00% | −70,396−100.0% | Sold out |
| Atom Investors LP | 0 | $0 | 0.00% | −54,762−100.0% | Sold out |
| Standard Life Aberdeen plc | 0 | $0 | 0.00% | −23,735−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −14,827−100.0% | Sold out |
| Ameriprise Financial Inc | 0 | $0 | 0.00% | −12,000−100.0% | Sold out |
| Manufacturers Life Insurance Company, The | 0 | $0 | 0.00% | −11,555−100.0% | Sold out |
| Bender Robert & Associates | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Lazard Asset Management LLC | 0 | $0 | 0.00% | −5,453−100.0% | Sold out |
| Capital Investment Advisors, LLC | 0 | $0 | 0.00% | −3,000−100.0% | Sold out |
| Steward Partners Investment Advisory, LLC | 0 | $0 | 0.00% | −1,600−100.0% | Sold out |
| Sowell Financial Services LLC | 0 | $0 | 0.00% | −51−100.0% | Sold out |